D Scott McMeekin1, Michael W Sill2, Joan L Walker3, Kathleen N Moore4, Steven E Waggoner5, Premal H Thaker6, Tina Rizack7, James S Hoffman8, Paula M Fracasso9. 1. University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States. Electronic address: scott-mcmeekin@ouhsc.edu. 2. NRG Oncology Statistics and Data Management Center, Buffalo, NY, United States. Electronic address: msill@gogstats.org. 3. University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States. Electronic address: joan-walker@ouhsc.edu. 4. University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States. Electronic address: kathleen-moore@ouhsc.edu. 5. Case Western Reserve University, Cleveland, OH, United States. Electronic address: steven.waggoner@uhhospitals.org. 6. Washington University School of Medicine, St. Louis, MO, United States. Electronic address: thakerp@wudosis.wustl.edu. 7. Women and Infants, Providence, RI, United States. Electronic address: trizack@wihri.org. 8. The Hospital of Central Connecticut, New Britain, CT, United States. Electronic address: james.hoffman@hhchealth.org. 9. University of Virginia, Charlottesville, VA, United States. Electronic address: fracasso@virginia.edu.
Abstract
OBJECTIVE: To determine the maximum tolerated dose (MTD) of a modified paclitaxel/doxorubicin/cisplatin (TAP) regimen which incorporated intraperitoneal (IP) paclitaxel or IP paclitaxel/cisplatin in advanced endometrial cancer. METHODS: Patients (pts) with FIGO (1998) Stage IIIA/IIIC with positive cytologic washings/ascites, adnexa, or serosa or Stage IV (intraperitoneal disease spread), histologically confirmed endometrial cancer were eligible. The study was designed as a phase I, 3+3 dose escalation study evaluating 5 dose levels (DL). All pts received cycles 1-2 with IV TAP, and cycles 3-6 with IV/IP therapy, on a 21day schedule. Adverse events were evaluated on cycles 3-4 for dose limiting toxicity (DLT) and dose escalation decisions. RESULTS: Twenty-one pts were enrolled, of which 17 were evaluable for DLT. Most pts had Stage IV disease (76%) and serous/clear cell histology (59%). The MTD was determined to be DL 3 (cycles 3-6 including paclitaxel 90mg/m(2) IP, doxorubicin 45mg/m(2) IV, cisplatin 50mg/m(2)). Three DLT events occurred and were related to grades 3-4 metabolic toxicities. There was one grade 2 sensory neuropathy event and myelosupression was tolerable without the use of G-CSF. 88% of evaluable pts completed 6cycles of therapy. With a median follow-up of 22months, 46% of patients remain progression-free at 2years. CONCLUSION: We described an IV/IP based modification of a standard TAP regimen in endometrial cancer. Based on the high rate of completing 6cycles of therapy, low rates of neuropathy, and promising PFS, further study of IP therapy in endometrial cancer is warranted.
OBJECTIVE: To determine the maximum tolerated dose (MTD) of a modified paclitaxel/doxorubicin/cisplatin (TAP) regimen which incorporated intraperitoneal (IP) paclitaxel or IP paclitaxel/cisplatin in advanced endometrial cancer. METHODS:Patients (pts) with FIGO (1998) Stage IIIA/IIIC with positive cytologic washings/ascites, adnexa, or serosa or Stage IV (intraperitoneal disease spread), histologically confirmed endometrial cancer were eligible. The study was designed as a phase I, 3+3 dose escalation study evaluating 5 dose levels (DL). All pts received cycles 1-2 with IV TAP, and cycles 3-6 with IV/IP therapy, on a 21day schedule. Adverse events were evaluated on cycles 3-4 for dose limiting toxicity (DLT) and dose escalation decisions. RESULTS: Twenty-one pts were enrolled, of which 17 were evaluable for DLT. Most pts had Stage IV disease (76%) and serous/clear cell histology (59%). The MTD was determined to be DL 3 (cycles 3-6 including paclitaxel 90mg/m(2) IP, doxorubicin 45mg/m(2) IV, cisplatin 50mg/m(2)). Three DLT events occurred and were related to grades 3-4 metabolic toxicities. There was one grade 2 sensory neuropathy event and myelosupression was tolerable without the use of G-CSF. 88% of evaluable pts completed 6cycles of therapy. With a median follow-up of 22months, 46% of patients remain progression-free at 2years. CONCLUSION: We described an IV/IP based modification of a standard TAP regimen in endometrial cancer. Based on the high rate of completing 6cycles of therapy, low rates of neuropathy, and promising PFS, further study of IP therapy in endometrial cancer is warranted.
Authors: Andrea Mariani; Maurice J Webb; Gary L Keeney; Michael G Haddock; Giacomo Aletti; Karl C Podratz Journal: Gynecol Oncol Date: 2002-10 Impact factor: 5.482
Authors: Marcus E Randall; Virginia L Filiaci; Hyman Muss; Nick M Spirtos; Robert S Mannel; Jeffrey Fowler; J Tate Thigpen; Jo Ann Benda Journal: J Clin Oncol Date: 2005-12-05 Impact factor: 44.544
Authors: M Markman; B N Bundy; D S Alberts; J M Fowler; D L Clark-Pearson; L F Carson; S Wadler; J Sickel Journal: J Clin Oncol Date: 2001-02-15 Impact factor: 44.544
Authors: Gini F Fleming; Virginia L Brunetto; David Cella; Katherine Y Look; Gary C Reid; Adnan R Munkarah; Richard Kline; Robert A Burger; Annekathryn Goodman; R Tucker Burks Journal: J Clin Oncol Date: 2004-06-01 Impact factor: 44.544
Authors: T Onda; H Yoshikawa; K Mizutani; M Mishima; H Yokota; H Nagano; Y Ozaki; A Murakami; K Ueda; Y Taketani Journal: Br J Cancer Date: 1997 Impact factor: 7.640
Authors: Nick M Spirtos; Danielle Enserro; Howard D Homesley; Susan K Gibbons; David Cella; Robert T Morris; Koen DeGeest; Roger B Lee; David S Miller Journal: Gynecol Oncol Date: 2019-04-30 Impact factor: 5.482
Authors: Heidi Rütten; Cornelia Verhoef; Willem Jan van Weelden; Anke Smits; Joëlle Dhanis; Nelleke Ottevanger; Johanna M A Pijnenborg Journal: Cancers (Basel) Date: 2021-12-14 Impact factor: 6.639